explore -WSS

explore

author：hotspot 2025-09-30 22:05:03 - browse：4432

Cambridge: AbbVie — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 — nearly a million dollars more than the company has ever spent in a single quarter. Ruby Wallau for STAT

WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 alone — more than any other drugmaker spent in the same period, and nearly a million dollars more than the company spent in the same period last year.

AbbVie was the seventh-highest corporate lobbying spender last quarter, ahead of giants like Lockheed Martin, CVS Health, and, AT&T, federal records show.

The number is eye-popping even for the pharmaceutical industry, which is known for its omnipresence on Capitol Hill, and its nearly unlimited lobbying budgets.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： IRA could hurt research into orphan drugs for rare diseases

knowledge

hotspot

WSS

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Methadone treatment changes are coming. Do they go far enough?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Gene editing the human germline: What are the risks?

Virtual Event: March of the Biosimilars

leisure time

explore

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

FDA proposes changes to key medical devices approval pathway

At least 13 dead in Texas as scorching temps continue

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Trump demands the U.S. pay no more for drugs than other countries … again

Regeneron agrees to White House price limits on anti

Guidelines to prevent youth baseball injuries need more muscle

Neuroscience’s long legacy of racism

How one medical school became remarkably diverse

Colonoscopy prep: Liquid

focus

Telehealth for opioid use disorder is lifesaving

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

IRA could hurt research into orphan drugs for rare diseases

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

FDA approves updated Covid vaccines

Long Covid needs a new name — and a new frame

knowledge

hotspot

leisure time

focus